ArticleJournal of market access & health policy2015

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.

Xavier Roblin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.